144 results
Page 5 of 8
8-K
EX-99.1
ezhy7n
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-99.1
2y4w6c d5c0q9
27 May 21
Regulation FD Disclosure
7:01am
8-K
EX-99.1
9mb50q13s
1 Apr 21
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
6:55am
8-K
EX-99.2
hrnj0dcx
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-99.1
k21ka b5q8mrdss08y0
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
e7hh2m0x7z7r
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-2.1
1jde8ks a2n
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-99.1
52qs 87xv
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-99.1
b8f5hd7epczrexnzju
31 Mar 20
EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study
6:55am
8-K
EX-10.1
ktknkf9i6x iec
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.1
t98893rxniqh
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.2
n5qo4h dd
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm